Kura Oncology
Ms. Bair joined Kura with more than 25 years of combined in-house and law firm experience, serving most recently as General Counsel and Senior Vice President, Administration at Athenex. She played a key role in leading the organization through its evolution from a private, preclinical-stage company to a global, publicly traded biopharmaceutical company, directly contributing to multiple NDA filings and an FDA approval. Previously, she was a partner at Harris Beach PLLC, advising business clients, including Fortune 500 companies, across diverse industries on commercial litigation matters. Ms. Bair serves on the Boards of Directors of BirchBioMed Inc., the University at Buffalo Law Alumni Association and the Western New York Women’s Foundation. She also serves on the Board of Trustees of the University at Buffalo Foundation as well as the Advisory Boards of Varia Ventures and the Buffalo Institute for Genomics & Data Analytics. She earned her J.D. from State University of New York at Buffalo School of Law and her B.S. in administration from Bowling Green State University.
This person is not in any offices
Kura Oncology
20 followers
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our small-molecule drug candidates target signaling pathways and other drivers of cancer where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment.